Cancer F (2024) & Fig. 2022. (n.d.). Retrieved August 2, from https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html

Retrieved (2024) August 2, from https://seer.cancer.gov/statfacts/html/mulmy.html

Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D’Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Snedeker J (2023) Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. https://doi.org/10.6004/jnccn.2023.0061

Cancer Today. (n.d.). Retrieved August 2 (2024) from https://gco.iarc.who.int/today/

Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, McGlynn KA, Landgren O (2010) Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116(25):5501–5506. https://doi.org/10.1182/blood-2010-07-298760

Article  PubMed  PubMed Central  Google Scholar 

Turesson I, Velez R, Kristinsson SY, Landgren O (2010) Patterns of Improved Survival in patients with multiple myeloma in the twenty-First Century: a Population-based study. J Clin Oncol 28(5):830–834. https://doi.org/10.1200/JCO.2009.25.4177

Article  PubMed  Google Scholar 

Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkholm M (2007) Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncology: Official J Am Soc Clin Oncol 25(15):1993–1999. https://doi.org/10.1200/JCO.2006.09.0100

Article  Google Scholar 

Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau J-L, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD & Multiple myeloma (010) study investigators. (2007). Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med, 357(21), 2123–2132. https://doi.org/10.1056/NEJMoa070594

Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern Cooperative Oncology Group (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncology: Official J Am Soc Clin Oncol 24(3):431–436. https://doi.org/10.1200/JCO.2005.03.0221

Article  Google Scholar 

Osman K, Comenzo R, Rajkumar SV (2001) Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344(25):1951–1952. https://doi.org/10.1056/NEJM200106213442516

Article  PubMed  Google Scholar 

Zangari M, Berno T, Zhan F, Tricot G, Fink L (2012) Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs. Semin Thromb Hemost 38(8):768–779. https://doi.org/10.1055/s-0032-1328888

Article  PubMed  Google Scholar 

Cini M, Zamagni E, Valdré L, Palareti G, Patriarca F, Tacchetti P, Legnani C, Catalano L, Masini L, Tosi P, Gozzetti A, Cavo M (2010) Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. Eur J Haematol 84(6):484–492. https://doi.org/10.1111/j.1600-0609.2010.01434.x

Article  PubMed  Google Scholar 

Carrier M, Le Gal G, Tay J, Wu C, Lee AY (2011) Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 9(4):653–663. https://doi.org/10.1111/j.1538-7836.2011.04215.x

Article  PubMed  Google Scholar 

Schoen MW, Carson KR, Luo S, Gage BF, Li A, Afzal A, Sanfilippo KM (2020) Venous thromboembolism in multiple myeloma is associated with increased mortality. Res Pract Thromb Haemostasis 4(7):1203–1210. https://doi.org/10.1002/rth2.12411

Article  Google Scholar 

Kristinsson SY, Pfeiffer RM, Björkholm M, Goldin LR, Schulman S, Blimark C, Mellqvist U-H, Wahlin A, Turesson I, Landgren O (2010) Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 115(24):4991–4998. https://doi.org/10.1182/blood-2009-11-252072

Article  PubMed  PubMed Central  Google Scholar 

Chakraborty R, Rybicki L, Valent J, Garcia AVM, Faiman BM, Khouri J, Samaras CJ, Anwer F, Khorana AA (2021) Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy. Blood Cancer J 11(6):121. https://doi.org/10.1038/s41408-021-00513-4

Article  PubMed  PubMed Central  Google Scholar 

Swan D, Rocci A, Bradbury C, Thachil J (2018) Venous thromboembolism in multiple myeloma—choice of prophylaxis, role of direct oral anticoagulants and special considerations. Br J Haematol 183(4):538–556. https://doi.org/10.1111/bjh.15684

Article  PubMed  Google Scholar 

Gogia A, Sikka M, Sharma S, Rusia U (2018) Hemostatic abnormalities in multiple myeloma patients. Asian Pac J Cancer Prevention: APJCP 19(1):127–130. https://doi.org/10.22034/APJCP.2018.19.1.127

Article  Google Scholar 

Thorsteinsdottir S, Gislason G, Aspelund T, Sverrisdottir I, Landgren O, Turesson I, Björkholm M, Kristinsson SY (2020) Fractures and survival in multiple myeloma: results from a population-based study. Haematologica 105(4):1067–1073. https://doi.org/10.3324/haematol.2019.230011

Article  PubMed  PubMed Central  Google Scholar 

Gaddh M, Antun A, Yamada K, Gupta P, Tran H, El Rassi F, Kim HS, Khoury HJ (2014) Venous access catheter-related thrombosis in patients with cancer. Leuk Lymphoma 55(3):501–508. https://doi.org/10.3109/10428194.2013.813503

Article  PubMed  Google Scholar 

Horváth-Puhó E, Suttorp MM, Frederiksen H, Hoekstra T, Dekkers OM, Pedersen L, Cannegieter SC, Dekker FW, Sørensen HT (2018) Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma. Clin Epidemiol 10:1371–1380. https://doi.org/10.2147/CLEP.S172306

Article  PubMed  PubMed Central  Google Scholar 

Uaprasert N, Voorhees PM, Mackman N, Key NS (2010) Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. Eur J Cancer (Oxford England: 1990) 46(10):1790–1799. https://doi.org/10.1016/j.ejca.2010.03.007

Article  Google Scholar 

Li X, Sun X, Fang B, Leng Y, Sun F, Wang Y, Wang Q, Jin J, Yang M, Xu B, Fang Z, Chen L, Chen Z, Yang Q, Zhang K, Ye Y, Geng H, Sun Z, Hao D, Li J (2023) Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myeloma. Thromb J 21(1):105. https://doi.org/10.1186/s12959-023-00534-y

Article  PubMed  PubMed Central  Google Scholar 

Koh Y, Bang S-M, Lee JH, Yoon H-J, Do Y-R, Ryoo H-M, Lee N, Kim SJ, Kim K, Yoon S-S, Won J-H, Mun Y-C, Lee M-H, Rhee K-H, Kim H-J, Eom H, Kim MK, Shin HC (2010) Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Ann Hematol 89(2):201–206. https://doi.org/10.1007/s00277-009-0807-6. & Korean Multiple Myeloma Working Party

Article  PubMed  Google Scholar 

Brown JD, Adams VR (2016) Incidence and risk factors of thromboembolism with multiple myeloma in the Presence of Death as a competing risk: an empirical comparison of statistical methodologies. Healthcare 4(1):16. https://doi.org/10.3390/healthcare4010016

Article  PubMed  PubMed Central  Google Scholar